Stocktoria
Vericel Corp VCEL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1997-02-04
Vericel Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 74.4% | 72.6% | 68.6% | 66.8% | 67.9% |
| Operating margin | 4.0% | 1.9% | -3.3% | -10.4% | -5.0% |
| Net margin | 6.0% | 4.4% | -1.6% | -10.2% | -4.8% |
| FCF margin | 9.0% | -2.4% | 7.7% | 6.1% | 13.5% |
| Return on assets | 3.4% | 2.4% | -0.9% | -6.1% | -3.1% |
| Return on equity | 4.7% | 3.5% | -1.4% | -8.7% | -4.4% |
| Current ratio | 5.03 | 4.23 | 4.49 | 4.99 | 6.08 |
| Revenue growth | 16.5% | 20.1% | 20.2% | 5.2% | 25.8% |
Source: SEC EDGAR filings · CIK 0000887359 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.